Targeted in vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform
June 22, 2023
Download the poster here.
Download the poster here.
Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today announced that it has raised $76 million in an oversubscribed Series A financing.